NetworkNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Closes $16.7M IPO
RenovoRx (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, has closed its underwritten initial public offering of 1,850,000 units at a public offering price per unit of $9.00. According to the update, RenovoRx offered all of the units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. The warrants have a $10.80 exercise price per share and are exercisable for a period of five years after the issuance date. In addition, RenovoRx granted the underwriters a 45-day option to purchase up to an additional 277,500 shares…







